Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers
- 1Department of Infectious Disease, Shaoyang Central Hospital
- 2Department of General Medicine, the Second Affiliated Hospital of Wannan Medical College
- 3Department of Dermatology, Xuancheng People’s Hospital
Abstract
In June 2026, satri-cel/CT041, a chimeric antigen receptor (CAR) T-cell product targeting Claudin18.2, received approval from China’s National Medical Products Administration for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after failure of at least two prior lines of therapy. This marks the first CAR-T product approved worldwide for solid tumours. The approval ends the long-standing debate over whether CAR-T cells can be effective against solid malignancies, yet it simultaneously raises a more pointed issue: in its pivotal randomised controlled trial, median progression-free survival was 3.25 months (95% CI 2.86-4.53) with satri-cel against 1.77 months (95% CI 1.61-2.04) with treatment of physician’s choice, giving a hazard ratio of 0.37 (95% CI 0.24-0.56). The two medians differ by 1.48 months; that figure marks where each survival distribution is cut in half and is not the benefit any individual patient can expect, and approval does not equate to a cure. Taking this as a starting point, this review systematically dissects the immunological bottlenecks that constrain CAR-T efficacy in gastrointestinal tumours. We first trace the evidence chain from phase I studies through the randomised controlled trial to exploratory adjuvant-therapy settings and then integrate the landscape of targets—Claudin18.2, glypican-3, carcinoembryonic antigen, mesothelin, and CDH17—within a target-tumour matrix encompassing gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer. The core section focuses on four intertwined immunological constraints: spatiotemporal heterogeneity and escape at the antigen level; a therapeutic window shaped jointly by epitope masking within tight junctions and immune privilege of the gastric mucosal stem cell niche—this mechanism not only explains why Claudin18.2-directed CAR-T cells exhibit an acceptable safety profile despite target expression on normal tissues but also provides a paradigm for rational selection of next-generation targets; a suppressive microenvironment composed of regulatory T cells, myeloid-derived suppressor cells, tumour-associated macrophages, transforming growth factor-β, adenosine, and a hypoxic and acidotic metabolic milieu; and CAR-T exhaustion driven by chronic antigen stimulation. We particularly emphasise that metabolic stress and exhaustion are not two parallel obstacles. We put forward a mechanistic model in which persistent antigen stimulation combined with intratumoral hypoxia acts as a “double hit”: through mitochondrial dysfunction and reactive oxygen species accumulation, the two inputs raise nuclear factor of activated T-cell (NFAT) activity and so drive the TOX/NR4A-dominated exhaustion program. This model is assembled from chronic-infection and mouse tumour systems and has not been tested in human CAR-T cells or in satri-cel-treated patients. We advance it as a framework for organising the four bottlenecks and for explaining why single-point interventions struggle to lift the efficacy ceiling, not as a demonstrated account. On this basis, we discuss strategies such as armouring, logic gating, transcription factor engineering, gene editing, and chemokine receptor modification, along with combination regimens involving checkpoint inhibition, oncolytic viruses, locoregional administration, and microbiome modulation, and we evaluate alternative platforms including CAR-macrophages, CAR-NK cells, and in vivo CAR-T generation. The watershed has been crossed, but the work of turning 3 months into 30 has only just begun.
Related
- Deciphering the prognostic and immunological landscape of NFKBIA across human cancers
- Socioeconomic inequalities, phenotypic aging, and the risk of incident upper gastrointestinal cancers
- Nonpharmacological interventions for frailty and sarcopenia in older adults with gastrointestinal cancers: A Bayesian network meta-analysis
- WRN helicase addiction in MSI-H colorectal cancer: biomarker-guided pharmacology, resistance evolution, and implications for other gastrointestinal cancers
- Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status
BibTeX
@article{zeng2026only,
title = {{Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers}},
author = {Liping Zeng and Sheng Wei and Nan Chen and Xiangping Xie},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1942381},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1942381/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers
AU - Liping Zeng
AU - Sheng Wei
AU - Nan Chen
AU - Xiangping Xie
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1942381
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1942381/full
AB - In June 2026, satri-cel/CT041, a chimeric antigen receptor (CAR) T-cell product targeting Claudin18.2, received approval from China’s National Medical Products Administration for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after failure of at least two prior lines of therapy. This marks the first CAR-T product approved worldwide for solid tumours. The approval ends the long-standing debate over whether CAR-T cells can be effective against solid malignancies, yet it simultaneously raises a more pointed issue: in its pivotal randomised controlled trial, median progression-free survival was 3.25 months (95% CI 2.86-4.53) with satri-cel against 1.77 months (95% CI 1.61-2.04) with treatment of physician’s choice, giving a hazard ratio of 0.37 (95% CI 0.24-0.56). The two medians differ by 1.48 months; that figure marks where each survival distribution is cut in half and is not the benefit any individual patient can expect, and approval does not equate to a cure. Taking this as a starting point, this review systematically dissects the immunological bottlenecks that constrain CAR-T efficacy in gastrointestinal tumours. We first trace the evidence chain from phase I studies through the randomised controlled trial to exploratory adjuvant-therapy settings and then integrate the landscape of targets—Claudin18.2, glypican-3, carcinoembryonic antigen, mesothelin, and CDH17—within a target-tumour matrix encompassing gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer. The core section focuses on four intertwined immunological constraints: spatiotemporal heterogeneity and escape at the antigen level; a therapeutic window shaped jointly by epitope masking within tight junctions and immune privilege of the gastric mucosal stem cell niche—this mechanism not only explains why Claudin18.2-directed CAR-T cells exhibit an acceptable safety profile despite target expression on normal tissues but also provides a paradigm for rational selection of next-generation targets; a suppressive microenvironment composed of regulatory T cells, myeloid-derived suppressor cells, tumour-associated macrophages, transforming growth factor-β, adenosine, and a hypoxic and acidotic metabolic milieu; and CAR-T exhaustion driven by chronic antigen stimulation. We particularly emphasise that metabolic stress and exhaustion are not two parallel obstacles. We put forward a mechanistic model in which persistent antigen stimulation combined with intratumoral hypoxia acts as a “double hit”: through mitochondrial dysfunction and reactive oxygen species accumulation, the two inputs raise nuclear factor of activated T-cell (NFAT) activity and so drive the TOX/NR4A-dominated exhaustion program. This model is assembled from chronic-infection and mouse tumour systems and has not been tested in human CAR-T cells or in satri-cel-treated patients. We advance it as a framework for organising the four bottlenecks and for explaining why single-point interventions struggle to lift the efficacy ceiling, not as a demonstrated account. On this basis, we discuss strategies such as armouring, logic gating, transcription factor engineering, gene editing, and chemokine receptor modification, along with combination regimens involving checkpoint inhibition, oncolytic viruses, locoregional administration, and microbiome modulation, and we evaluate alternative platforms including CAR-macrophages, CAR-NK cells, and in vivo CAR-T generation. The watershed has been crossed, but the work of turning 3 months into 30 has only just begun.
SN - 1664-3224
ER -